http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고윤석,장윤혜,김우성,이재담,오순환,김원동,Koh, Youn-Suck,Jang, Yun-Hae,Kim, Woo-Sung,Lee, Jae-Dam,Oh, Soon-Hwan,Kim, Won-Dong 대한결핵및호흡기학회 1994 Tuberculosis and Respiratory Diseases Vol.41 No.5
연구배경: ARDS발생 기전에 있어 TNF-$\alpha$나 IL-$1{\beta}$의 역할은 이들이 폐혈관 내피세포에 작용하여 모세혈관의 투과성을 증가시키는 것으로 추정되나 ARDS환자 발생 예측 지표로서의 TNF-$\alpha$ 및 IL-$1{\beta}$의 임상적 유용성에 대한 지금까지의 연구결과는 부정적이다. 이는 기존연구들이 다양한 질환들을 대상으로 함으로써 ARDS 발생기전의 다양성이 ARDS환자 발생 예측지표로서의 TNF-$\alpha$의 유용성을 부정적으로 나타나게하였을 가능성을 배제할 수 없다. 이에 저자들은 ARDS 발생이 내독소와 cytokines등에 의한 작용인 것으로 알려지고 있는 패혈증 증후군 환자들을 대상으로 TNF-$\alpha$와 IL-$1{\beta}$의 ARDS 발생의 예측 표지자로서 임상적 효용성을 검토하고자 본 연구를 시행하였다. 방법: 패혈증 증후군환자들을 대상으로 ARDS발생군(이하 ARDS군, 16명)과 호흡부전 상태에서 ARDS로는 진행하지않은 급성호흡 부전군(Acute hypoxemic respiratory failure group, 이하 AHRF군, 20명)으로 분류하여 등록시, 24시간 및 72시간후에 채혈하여 ARDS군은 ARDS 발생시에, AHRF군은 동맥혈 산소분압에 대한 폐포 산소분압의 비가 가장 낮은 시점의 TNF-$\alpha$와 IL-$1{\beta}$의 농도를 비교하였다. 또한 ARDS 및 AHRF군에서 쇽 발생군과 비발생군으로 분류하고 쇽 발생시에 측정된 TNF-$\alpha$와 IL-$1{\beta}$를 비발생군의 TNF-$\alpha$ 및 IL-$1{\beta}$의 값과 비교하였다. 대조군은 건강 대조군으로서 1회만 채혈하였다. 결과: 1) 혈중 TNF-$\alpha$의 농도: 본 연구에 사용한 Predicta kit의 TNF-$\alpha$ 농도 측정의 민감도는 평균${\pm}2$표준편차의 하한값이 10pg/mL이며, 특이도는 100%로, ARDS군 16명중 8명이, AHRF군 20명중 12명이 10pg/mL 이상으로 측정되어 두 군사이에서 혈중 TNF-$\alpha$가 10pg/mL 이상 발현된 비율의 차이는 없었다. ARDS 및 AHRF군의 혈중 TNF-$\alpha$의 중앙값 농도는 각각 10.26pg/mL(<10-16.99pg/mL, 사분위수범위, interquartile range), 10.82pg/mL(<10-20.38pg/mL)로서 두 군 사이에는 유의한 차이가 없었으며 (Fig. 1), ARDS 발생 전후의 혈중 TNF-$\alpha$의 농도도 중앙값이 10pg/mL미만(<10-15.32)pg/mL 및 10pg/mL미만(<10-10.22)pg/mL로서 유의한 차이가 없었고 6명중 2명만이 ARDS 발생 전에 비하여 TNF-$\alpha$의 값이 증가되었다. ARDS 및 AHRF군에서 패혈성 쇽이 발생한 환자들(26명)의 TNF-$\alpha$의 농도는 12.53(<10-20.82)pg/mL로서 비발생군(10명) <10pg/mL에 비해 유의하게 높았으나(p<0.01)(Fig. 2), 전체 생존군(<10, <10-12.92pg/mL)과 사망군(11.80, <10-20.8pg/mL)사이에는 유의한 차이가 없었다(P=0.28). 2) 혈중 IL-$1{\beta}$의 농도: 본 연구에 사용한 Quantikine kit의 최저 측정치는 0.3ng/mL로서 건강 대조군 10명중 1명을 제외한 모두에서 IL-$1{\beta}$측정치가 0.3pg/mL이하였다. ARDS 및 AHRF군의 검체 중 0.3ng/mL 이하로 측정된 경우는 ARDS, AHRF군에서 각각 1예가 있었다 ARDS 및 AHRF군의 혈중 IL-$1{\beta}$의 농도는 각각 2.22(1.37-8.01)ng/mL, 2.13(0.83-5.29)ng/mL으로서 두 군사이에는 유의한 차이가 없었으며(Fig. 3), ARDS 발생전(2.53, 0.3-8.38ng/mL)과 발생후(5.35, 0.66-11.51ng/mL)에서도 차이가 없었다. 패혈성 쇽 발생군(2.51, 1.28-8.34ng/mL)과 비발생군(1.46, 0.15-2.13ng/mL)사이에서는 통계적인 유의한 차이는 없었으나 비발생군에서 낮은 경향을 보였다(각각 P=0.44, P=0.054)(Fig. 4). 생존군과 Background: Tumor necrosis factor(TNF)-$\alpha$ and Interleukin(lL)-$1{\beta}$ are thought to play a major role in the pathogenesis of the septic syndrome, which is frequently associated with adult respiratory distress syndrome(ARDS). In spite of many reports for the role of TNF-$\alpha$ in the pathogenesis of ARDS, including human studies, it has been reported that TNF-$\alpha$ is not sensitive and specific marker for impending ARDS. But there is a possibility that the results were affected by the diversity of pathogenetic mechanisms leading to the ARDS because of various underlying disorders of the study group in the previous reports. The purpose of the present study was to evaluate the roles of TNF-$\alpha$ and IL-$1{\beta}$ as a predictable marker for development of ARDS in the patients with septic syndrome, in which the pathogenesis is believed to be mainly cytokine-mediated. Methods: Thirty-six patients of the septic syndrome hospitalized in the intensive care units of the Asan Medical Center were studied. Sixteens suffered from ARDS, whereas the remaining 20 were at the risk of developing ARDS(acute hypoxemic respiratory failure, AHRF). In all patients venous blood samples were collected in heparin-coated tubes at the time of enrollment, at 24 and 72 h thereafter. TNF-$\alpha$ and IL-$1{\beta}$ was measured by an enzyme-linked immunosorbent assay (ELISA). All data are expressed as median with interquartile range. Results: 1) Plama TNF-$\alpha$ levels: Plasma TNF-$\beta$ levels were less than 10pg/mL, which is lowest detection value of the kit used in this study within the range of the $mean{\pm}2SD$, in all of the normal controls, 8 of 16 subjects of ARDS and in 8 in 20 subjects of AHRF. Plasma TNF-$\alpha$ levels from patients with ARDS were 10.26pg/mL(median; <10-16.99pg/mL, interquartile range) and not different from those of patients at AHRF(10.82, <10-20.38pg/mL). There was also no significant difference between pre-ARDS(<10, <10-15.32pg/mL) and ARDS(<10, <10-10.22pg/mL). TNF-$\alpha$ levels were significantly greater in the patients with shock than the patients without shock(12.53pg/mL vs. <10pg/mL) (p<0.01). There was no statistical significance between survivors(<10, <10-12.92pg/mL) and nonsurvivors(11.80, <10-20.8pg/mL) (P=0.28) in the plasma TNF-$\alpha$ levels. 2) Plasma IL-$1{\beta}$ levels: Plasma IL-$1{\beta}$ levels were less than 0.3ng/mL, which is the lowest detection value of the kit used in this study, in one of each patients group. There was no significant difference in IL-$1{\beta}$ levels of the ARDS(2.22, 1.37-8.01ng/mL) and of the AHRF(2.13, 0.83-5.29ng/mL). There was also no significant difference between pre-ARDS(2.53, <0.3-8.34ngfmL) and ARDS(5.35, 0.66-11.51ng/mL), and between patients with septic shock and patients without shock (2.51, 1.28-8.34 vs 1.46, 0.15-2.13ng/mL). Plasma IL-$1{\beta}$ levels were significantly different between survivors(1.37, 0.4-2.36ng/mL) and nonsurvivors(2.84, 1.46-8.34ng/mL). Conclusion: Plasma TNF-$\alpha$ and IL-$1{\beta}$ level are not a predictable marker for development of ARDS. But TNF-$\alpha$ is a marker for shock in septic syndrome. These result could not exclude a possibility of pathophysiologic roles of TNF-$\alpha$ and IL-$1{\beta}$ in acute lung injury because these cytokine could be locally produced and exert its effects within the lungs.
B 형 간염바이러스와 연관된 각종 간질환군에서의 혈중 Alphal - Antitrypsin 치의 의의
고윤석(Youn Suck Koh),류우진(Woo Jin Lew),윤호주(Ho Ju Yun),함준수(Joon Soo Hahm),이종철(Jong Chul Rhee),이민호(Min Ho Lee),기춘석(Choon Suhk Kee),박경남(Kyung Nam Park) 대한내과학회 1988 대한내과학회지 Vol.35 No.1
N/A We studied the clinical significance the progress of of α1-antitrypsin (a-AT) as an indicator of hepatitis B virus related diseases, and as a marker of hepatoma by estimating the serum α1-AT level. The results are as follows: 1) The mean and standard deviation of the serum α1-AT level in each group was 198+30 mg/dl in healthy controls, 174±29mg/dl in healthy carriers, 263±68mg/ dl in acute viral hepatitis, 203±57 mg/dl in chronic viral hepatitis, 233±50mg/dl in chronic active hepatitis, 237±71mg/dl in liver cirrhosis, and 346±101mg/dl in hepatoma. 2) The α1-AT level of hepatoma showed the highest elevation in each group (p<0.05). 3) When using 330mg/dl of a-AT as the cut-off value of hepatoma, 27 of 52cases of hepatoma were included. In 20cases of hepatoma which were below 500ng/ml of alpha-Fetoprotein, 12 of the cases were above 330mg/dl of α1-AT. 4) When considering the convenience and laboratory cast of α1-AT, with the above results, we suggest that more extensive studies be done, in the areas of α1-AT as an indicator of the progress of hepatitis B virus related diseases, and as a complemental marker of hepatoma.
우리나라 일부 병원에서 환자, 보호자, 의료진의 연명치료 중지 관련 의사결정에 관한 태도 연구
권복규 ( Ivo Kwon ),고윤석 ( Youn Suck Koh ),윤영호 ( Young Ho Yun ),허대석 ( Dae Seog Heo ),서상연 ( Sang Yeon Seo ),김현철 ( Hyeon Chul Kim ),최경석 ( Kyung Suk Choi ),배현아 ( Hyun A Bae ),안경진 ( Kyung Jin Ahn ) 한국의료윤리학회 2010 한국의료윤리학회지 Vol.13 No.1
A survey was conducted from September to December 2008 to examine the attitudes of patients, family members, and physicians toward the withdrawal of medical treatment for terminal patients and other related issues. The subjects for the study were 91 cancer patients, 96 family members of cancer or other terminally ill patients, and 140 physicians. Most subjects acknowledge the need for an appropriate regulatory framework for the withdrawal of treatment for terminal patients. However, some discrepancies were found among the different groups (patients, family members, physicians) in this study. Patients showed a stronger preference for the withdrawal of treatment than did family members. Also, most patients claimed they wanted to receive the diagnosis of a terminal illness from their physician, while most family members seem to think it is their own duty to convey such a diagnosis to the patient. Both groups prefer co-decision-making about the withdrawal of treatment over individual decision-making by the patient. However, most family members admit that they do not know much about the patient`s wishes and lack the time for sufficient conversation with the patient. Physicians are skeptical of the authenticity of the decisions made by family members, and some physicians also regard hospital ethics committees as being ineffective for resolving these issues. The results of this study paint a unique picture of clinical culture in Korea, where family members still exert strong influence on clinical decision-making and little information is shared between patients, family members, and physicians. The study points to a need for greater public education in Korea on the practical and ethical issues surrounding the withdrawal of treatment for terminal patients.
국내 한 3차 병원 중환자실에 입원한 중증지역획득폐렴 환자의 원인 미생물과 경험적 항균제 치료 성적의 고찰
이재승 ( Jae Seung Lee ),정주원 ( Joo Won Chung ),고윤석 ( Yun Suck Koh ),임채만 ( Chae Man Lim ),정영주 ( Young Joo Jung ),오연목 ( Youn Mok Oh ),심태선 ( Tae Sun Shim ),이상도 ( Sang Do Lee ),김우성 ( Woo Sung Kim ),김동순 ( Don 대한결핵 및 호흡기학회 2005 Tuberculosis and Respiratory Diseases Vol.59 No.5
방사선 치료후 기관지-폐포세척액내 폐포대식세포 및 임파구의 접착분자발현 변화와 방사선에 의한 폐렴 및 폐섬유증발생의 예측인자로서의 의의
김동순 ( Dong Soon Kim ),백상훈 ( Sang Hoon Paik ),최은경 ( Eun Kyung Choi ),장혜숙 ( Hye Sook Chang ),최정은,임채만 ( Chae Man Lim ),고윤석 ( Yun Suck Koh ),이상도 ( Sang Do Lee ),김우성 ( Woo Sung Kim ),김원동 ( Won Dong Kim ) 대한결핵 및 호흡기학회 1996 Tuberculosis and Respiratory Diseases Vol.43 No.1